company overview

 

Cortice Biosciences is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic indications with urgent unmet medical need.

The company's lead drug candidate TPI 287 is a novel microtubule stabilizing taxoid with the unique property of being able to readily penetrate the blood-brain barrier. Cortice is developing this agent for treatment of cancers of the brain that are inaccessible to most chemotherapeutic agents due to poor brain penetration. Given the potential beneficial effect of microtubule stabilization as a treatment of neurodegenerative diseases known as tauopathies, Cortice is also developing TPI 287 for treatment of progressive supranuclear palsy, corticobasal dementia, and Alzheimer's disease.

Cortice is also developing a pipeline of small molecule beta1 adrenergic receptor modulators for the treatment of cognitive impairment. Lead compound CRT 001 is a repurposed drug that was previously on the market for treatment of heart failure, thereby potentially expediting further clinical development of this compound.